UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review

Journal of ovarian research, 2019-03, Vol.12 (1), p.28-28, Article 28

2019

Volltextzugriff (PDF)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Blood cancer journal (New York), 2023-02, Vol.13 (1), p.30-30, Article 30

2023

Volltextzugriff (PDF)

Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis

PloS one, 2011-04, Vol.6 (4), p.e18734-e18734

2011

Volltextzugriff (PDF)

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

Haematologica (Roma), 2017-03, Vol.102 (3), p.e112-e114

2017

Volltextzugriff (PDF)

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients

Clinical chemistry and laboratory medicine, 2024-11, Vol.62 (12), p.2507-2518

2024

Volltextzugriff (PDF)

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Blood, 2016-12, Vol.128 (25), p.2941-2948

2016

Volltextzugriff (PDF)

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

British journal of haematology, 2019-11, Vol.187 (3), p.319-327

2019

Volltextzugriff (PDF)

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study

Diagnostics (Basel), 2021-07, Vol.11 (7), p.1274-7

2021

Volltextzugriff (PDF)

Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center

Annals of Laboratory Medicine, 2018, 38(2), , pp.95-101

2018

Volltextzugriff (PDF)

Endometrial cancer: A systematic review of HE4, REM and REM-B

Clinica chimica acta, 2021-04, Vol.515, p.27-36

2021

Volltextzugriff (PDF)

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Clinical chemistry (Baltimore, Md.), 2021-12, Vol.67 (12), p.1689-1698

2021

Volltextzugriff (PDF)

Hyponatremia is associated with poor outcome in COVID-19

Journal of nephrology, 2021-08, Vol.34 (4), p.991-998

2021

Volltextzugriff (PDF)

Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences

Clinical biochemistry, 2018-01, Vol.51, p.72-79

2018

Volltextzugriff (PDF)

Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia

Diabetes & metabolism, 2020-09, Vol.46 (4), p.341-342

2020

Volltextzugriff (PDF)

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-05, Vol.19 (5), p.e228-e237

2019

Volltextzugriff (PDF)

Eltrombopag induces major non‐toxic hypersiderraemia

British journal of haematology, 2019-07, Vol.186 (2), p.365-366

2019

Volltextzugriff (PDF)

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

The Lancet (British edition), 2019-07, Vol.394 (10192), p.29-38

2019

Volltextzugriff (PDF)

Gamma heavy chain disease associated with rheumatoid arthritis: a case report

Journal of medical case reports, 2021-03, Vol.15 (1), p.121-121, Article 121

2021

Volltextzugriff (PDF)

Identification of 5-fluorocytosine as a new interfering compound in serum capillary zone electrophoresis

Clinical chemistry and laboratory medicine, 2017-03, Vol.55 (3), p.e56

2017

Volltextzugriff (PDF)

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

The lancet oncology, 2021-10, Vol.22 (10), p.1378-1390

2021

Volltextzugriff (PDF)

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial

Journal of clinical medicine, 2019-10, Vol.8 (11), p.1784

2019

Volltextzugriff (PDF)

IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up

Annales de biologie clinique (Paris), 2016-08, Vol.74 (4), p.429-441

2016

Volltextzugriff (PDF)

Effects of female increased body mass index on in vitro fertilization cycles outcome

Obesity research & clinical practice, 2015-07, Vol.9 (4), p.382-388

2015

Volltextzugriff (PDF)

Critical care testing: SFBC recommendations in 2018

Annales de biologie clinique (Paris), 2018-01, Vol.76 (1), p.23

2018

Volltextzugriff (PDF)

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

The lancet oncology, 2024-08, Vol.25 (8), p.1003-1014

2024

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(73)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study

Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center

Endometrial cancer: A systematic review of HE4, REM and REM-B

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Hyponatremia is associated with poor outcome in COVID-19

Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences

Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma

Eltrombopag induces major non‐toxic hypersiderraemia

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Gamma heavy chain disease associated with rheumatoid arthritis: a case report

Identification of 5-fluorocytosine as a new interfering compound in serum capillary zone electrophoresis

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial

IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up

Effects of female increased body mass index on in vitro fertilization cycles outcome

Critical care testing: SFBC recommendations in 2018

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Suchergebnisse filtern